Obsidian Therapeutics (NASDAQ:OBX) Now Covered by Analysts at Piper Sandler

Analysts at Piper Sandler began coverage on shares of Obsidian Therapeutics (NASDAQ:OBX) in a research note issued to investors on Wednesday,Benzinga reports. The firm set an “overweight” rating and a $42.00 price target on the stock. Piper Sandler’s price objective suggests a potential upside of 23.53% from the company’s current price.

Obsidian Therapeutics Trading Up 79.0%

Shares of OBX stock traded up $15.01 on Wednesday, reaching $34.00. The stock had a trading volume of 13,400 shares.

Obsidian Therapeutics is a biotechnology company focused on developing engineered cell and gene therapies for cancer and other serious diseases. The company’s approach is designed to improve the safety, control and effectiveness of therapeutic proteins and genetic medicines by enabling their activity to be regulated inside the body.

Obsidian’s technology platform, known as cytoDRiVE, uses small-molecule-controlled genetic systems to modulate the expression or activity of therapeutic proteins.